Sino Biopharmaceutical Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Jun'21

Mar'21

Dec'20

Sep'20

Jun'20

Mar'20

Dec'19

Net Sales

8,547.08

8,671.95

6,458.61

6,134.68

7,026.67

6,927.84

5,457.35

Other Operating Income

0.00

Total Operating income

8,547.08

8,671.95

6,458.61

6,134.68

7,026.67

6,927.84

5,457.35

Raw Material Cost

1,607.55

1,695.01

1,295.73

1,436.30

1,667.76

1,410.62

1,283.00

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

1,439.69

1,335.31

1,098.78

1,108.95

893.30

910.63

960.82

Power Cost

0.00

Manufacturing Expenses

90.82

85.80

67.73

102.06

91.74

100.69

107.36

Selling and Distribution Expenses

3,830.16

4,303.63

3,598.25

3,537.64

2,979.67

3,218.27

2,917.67

Other Expenses

-60.85

-20.64

-34.80

-77.83

-36.53

7.30

-68.57

Total Expenditure (Excl Depreciation)

6,359.70

7,213.35

5,712.50

5,406.66

5,267.17

5,713.20

4,583.18

Operating Profit (PBDIT) excl Other Income

2187.4

1458.6000000000001

746.1

728

1759.5

1214.6

874.2

Other Income

277.80

275.28

23.07

485.86

-179.41

144.76

313.29

Operating Profit (PBDIT)

2,718.65

1,963.07

1,296.92

1,717.26

1,919.52

1,741.14

1,768.59

Interest

90.82

85.80

67.73

102.06

91.74

100.69

107.36

Exceptional Items

64.06

-13.92

689.71

267.39

0.00

178.26

25.25

Gross Profit (PBDT)

6,939.53

6,976.94

5,162.87

4,698.37

5,358.91

5,517.22

4,174.36

Depreciation

253.48

229.19

527.74

503.38

339.43

381.74

581.12

Profit Before Tax

2,438.41

1,634.16

1,391.16

1,379.21

1,488.36

1,436.97

1,105.36

Tax

1,069.74

535.11

-123.19

268.55

360.70

241.03

63.52

Provisions and contingencies

0.00

Profit After Tax

7,893.26

2,291.01

1,076.84

713.83

398.93

975.16

501.25

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

7,893.26

2,291.01

1,076.84

713.83

398.93

975.16

501.25

Share in Profit of Associates

0.00

Minority Interest

817.77

575.79

535.17

345.84

680.96

223.55

655.79

Other related items

0.00

Consolidated Net Profit

8,711.03

2,866.80

1,612.01

1,059.67

1,079.90

1,198.71

1,157.04

Equity Capital

0.00

Face Value

0.0

0.03

0.0

Reserves

29,536.81

22,138.05

19,856.11

36,041.00

34,527.02

34,646.44

16,722.16

Earnings per share (EPS)

0.41

0.11

0.06

0.04

0.02

0.04

0.03

Diluted Earnings per share

0.41

0.11

0.06

0.04

0.02

0.04

0.03

Operating Profit Margin (Excl OI)

25.59%

16.82%

11.55%

11.87%

25.04%

17.53%

16.02%

Gross Profit Margin

31.49%

21.49%

29.71%

30.69%

26.01%

26.25%

30.9%

PAT Margin

92.35%

26.42%

16.67%

11.64%

5.68%

14.08%

9.18%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Jun 2021 is 21.64% vs -3.26% in Jun 2020

Consolidate Net Profit

YoY Growth in quarter ended Jun 2021 is 706.65% vs -18.76% in Jun 2020

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Jun 2021 is 16.29% vs 8.89% in Jun 2020

Interest

YoY Growth in quarter ended Jun 2021 is -0.98% vs 55.95% in Jun 2020

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Jun 2021 has improved from Jun 2020

Compare Quarterly Results Of Sino Biopharmaceutical Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(HKD)

Change(%)

Net Sales

8,547.08

Other Operating Income

0.00

Total Operating income

8,547.08

Raw Material Cost

1,607.55

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

1,439.69

Power Cost

0.00

Manufacturing Expenses

90.82

Selling and Distribution Expenses

3,830.16

Other Expenses

-60.85

0.00

-60.85

Total Expenditure (Excl Depreciation)

6,359.70

Operating Profit (PBDIT) excl Other Income

2,187.38

0.00

2,187.38

Other Income

277.80

Operating Profit (PBDIT)

2,718.65

Interest

90.82

Exceptional Items

64.06

Gross Profit (PBDT)

6,939.53

Depreciation

253.48

Profit Before Tax

2,438.41

Tax

1,069.74

Provisions and contingencies

0.00

Profit After Tax

7,893.26

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

7,893.26

Share in Profit of Associates

0.00

Minority Interest

817.77

Other related items

0.00

Consolidated Net Profit

8,711.03

Equity Capital

0.00

Face Value

0.00

Reserves

29,536.81

Earnings per share (EPS)

0.41

Diluted Earnings per share

0.41

Operating Profit Margin (Excl OI)

25.59%

0.00

25.59%

Gross Profit Margin

31.49%

0.00

31.49%

PAT Margin

92.35%

0.00

92.35%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 854.71 Million

in Jun 2021

Figures in Million

QoQ Growth in quarter ended Jun 2021 is -1.44% vs 34.27% in Mar 2021

YoY Growth in quarter ended Jun 2021 is 21.64% vs -3.26% in Jun 2020

Quarterly - Consolidate Net Profit

Consolidate Net Profit 871.10 Million

in Jun 2021

Figures in Million

QoQ Growth in quarter ended Jun 2021 is 203.86% vs 77.84% in Mar 2021

YoY Growth in quarter ended Jun 2021 is 706.65% vs -18.76% in Jun 2020

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 244.09 Million

in Jun 2021

Figures in Million

QoQ Growth in quarter ended Jun 2021 is 44.62% vs 32.49% in Mar 2021

YoY Growth in quarter ended Jun 2021 is 16.29% vs 8.89% in Jun 2020

Quarterly - Interest

Interest 9.08 Million

in Jun 2021

Figures in Million

QoQ Growth in quarter ended Jun 2021 is 5.83% vs 26.74% in Mar 2021

YoY Growth in quarter ended Jun 2021 is -0.98% vs 55.95% in Jun 2020

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 25.59%

in Jun 2021

Figures in %

QoQ Growth in quarter ended Jun 2021 has improved from Mar 2021

YoY Growth in quarter ended Jun 2021 has improved from Jun 2020